세계의 POC(Point of Care) 분자진단 시장 규모 : 제품 및 서비스별, 기술별, 용도별, 최종사용자별, 지역 범위별, 예측

Point Of Care Molecular Diagnostics Market Size And Forecast

Point Of Care Molecular Diagnostics Market size was valued at USD 3.61 Billion in 2024 and is projected to reach USD 8.35 Billion by 2032, growing at a CAGR of 12.2% from 2026 to 2032.

The Point of Care (POC) Molecular Diagnostics Market encompasses the development, production, and sale of diagnostic tests that detect and analyze genetic material (DNA or RNA) at or near a patient's location. Unlike traditional lab based molecular tests that require samples to be sent to a centralized facility for analysis, POC molecular diagnostics provide rapid results, often within minutes, enabling healthcare providers to make timely and informed clinical decisions. This market is driven by the miniaturization of complex lab processes onto compact, portable devices, often leveraging technologies like Polymerase Chain Reaction (PCR) and isothermal amplification. The primary objective is to improve healthcare accessibility, reduce turnaround times, and facilitate faster treatment initiation, particularly for infectious disease, genetic disorders, and oncology.

The significance of the POC Molecular Diagnostics Market lies in its ability to bridge the gap between traditional laboratory testing and immediate patient needs. Its applications are widespread, from emergency departments and physician's offices to remote clinics and even home care settings. Key drivers for this market include the increasing prevalence of infectious diseases, a growing need for rapid and decentralized diagnostic solutions, and advancements in microfluidic and lab on a chip technologies that integrate multiple testing steps into a single, user friendly platform. The COVID 19 pandemic served as a major catalyst, highlighting the critical role of rapid, accurate, and accessible molecular testing in disease surveillance and control. As a result, the market is poised for significant growth, with a growing focus on integrating technologies like AI and machine learning to further enhance diagnostic accuracy and efficiency.

Global Point Of Care Molecular Diagnostics Market Drivers

The Point of Care (POC) Molecular Diagnostics market is experiencing robust growth, driven by a convergence of factors that are reshaping the healthcare landscape. From public health crises to technological breakthroughs, these drivers are collectively pushing the industry toward a more decentralized, accessible, and patient centric model. The following analysis explores the key forces propelling this market forward, highlighting their impact on both the clinical and commercial spheres.

Rising Prevalence of Infectious Diseases: The increasing global incidence of infectious diseases, including well known pathogens like influenza, tuberculosis, and HIV, as well as emerging threats, is a primary driver for the Point of Care Molecular Diagnostics market. Traditional lab based diagnostics often have a long turnaround time, which can delay treatment and contribute to the spread of highly contagious illnesses. POC molecular diagnostics offer a crucial solution by providing rapid and accurate results at or near the patient, enabling immediate clinical decisions and effective infection control. The COVID 19 pandemic served as a powerful catalyst, demonstrating the indispensable role of rapid POC testing in managing outbreaks and conducting widespread surveillance. This heightened awareness and investment in infectious disease diagnostics have created a sustained demand for portable, user friendly molecular testing platforms.

Growing Demand for Rapid and Accurate Diagnostics: In modern healthcare, time is a critical factor, and the demand for rapid and accurate diagnostics has become a non negotiable market driver. Healthcare providers are increasingly prioritizing diagnostic tools that can deliver fast, reliable results to enable immediate clinical decision making. For conditions ranging from strep throat to sepsis, a speedy diagnosis can dramatically improve patient outcomes and reduce the need for unnecessary antibiotic prescriptions. POC molecular diagnostics, with their ability to provide lab quality results in minutes, directly address this need. This trend is further supported by the push for more efficient healthcare workflows, shorter hospital stays, and a reduction in the overall cost of care, as early and accurate diagnosis can prevent the progression of diseases and avoid more complex and expensive treatments later on.

Advancements in Molecular Diagnostic Technologies: The market is being significantly propelled by continuous advancements in molecular diagnostic technologies. Miniaturization of complex lab equipment, coupled with breakthroughs in microfluidics and nanotechnology, has led to the creation of highly compact, portable, and user friendly devices. These innovations allow for the integration of multiple testing steps onto a single "lab on a chip" platform. Furthermore, the incorporation of artificial intelligence (AI) and machine learning is enhancing the performance and usability of these devices by improving data analysis, reducing false positives, and providing automated interpretation of results. These technological leaps are making sophisticated molecular testing more accessible to a wider range of healthcare settings and users, from rural clinics to physicians' offices, thereby broadening the market's reach.

Increasing Decentralization of Healthcare Services: A fundamental shift towards the decentralization of healthcare services is a powerful driver for the POC molecular diagnostics market. As healthcare models evolve to prioritize patient convenience and accessibility, there is a growing demand for diagnostic solutions that can be used outside of traditional centralized laboratories. This includes the proliferation of outpatient care, home healthcare, and remote clinics. Portable and easy to use molecular diagnostic devices are perfectly suited for these settings, allowing healthcare providers to offer a full spectrum of care, from consultation to diagnosis and treatment, in a single visit. This trend is particularly impactful in regions with vast geographic areas or underserved communities, where the logistical challenges of centralized testing have historically been a barrier to timely care.

Need for Early Disease Detection: The need for early disease detection is a critical driver, as it is directly linked to better treatment outcomes and overall patient well being. Whether for infectious diseases, genetic disorders, or cancer, diagnosing a condition in its early stages can be the difference between a minor intervention and a life threatening illness. Point of care molecular diagnostics play a vital role in this by providing rapid, accurate screening and detection capabilities. For example, a quick POC test for a genetic predisposition or a viral infection can lead to a prompt and targeted therapeutic plan, minimizing the disease's impact on the patient. This emphasis on proactive and preventative healthcare, championed by both medical professionals and consumers, is fueling the adoption of these technologies across various clinical applications.

Global Point Of Care Molecular Diagnostics Market Restraints

Despite its immense potential to transform healthcare, the Point of Care (POC) Molecular Diagnostics market faces several significant restraints that hinder its widespread adoption. These challenges, ranging from economic hurdles to logistical complexities and regulatory obstacles, must be addressed for the market to reach its full potential, particularly in diverse global settings.

High Cost of Molecular Diagnostic Devices: The high cost of molecular diagnostic devices is a major restraint, particularly in low and middle income regions where healthcare budgets are limited. The advanced technology, complex components, and rigorous R&D required to develop these systems lead to high manufacturing and final purchase prices. This makes it difficult for smaller clinics, physicians' offices, and public health systems in developing economies to invest in and adopt these tools. Beyond the initial capital outlay, the recurring cost of consumables, such as specialized assays and reagents, further adds to the financial burden, creating a barrier to widespread implementation. The market is therefore often concentrated in well funded healthcare systems, while many underserved populations remain without access to these rapid diagnostic capabilities.

Limited Technical Expertise: The successful operation of some molecular diagnostic devices requires specialized training and technical expertise, which can be a significant challenge in resource limited and remote settings. While the industry is moving towards more user friendly, automated platforms, many systems still require meticulous sample preparation, precise handling of reagents, and careful interpretation of results to avoid errors. The lack of adequately trained personnel in many developing regions, and even in some decentralized settings in developed countries, can lead to inaccurate test results, operational inefficiencies, and a lack of trust in the technology. This skill gap necessitates ongoing investment in training and education programs, which can be an additional cost and logistical challenge for healthcare providers.

Stringent Regulatory Requirements: The development of new molecular diagnostic products is a complex process, subject to stringent regulatory requirements that can significantly delay market entry and commercialization. Regulatory bodies in key markets like the United States (FDA) and Europe (MDR) have rigorous and often lengthy approval processes to ensure the safety and efficacy of new devices. This creates a significant burden for manufacturers, particularly smaller innovative companies, as it requires substantial investment in clinical trials, validation studies, and extensive documentation. The complexity of navigating different regulatory frameworks across various countries also poses a challenge for global market expansion, slowing down the pace at which novel diagnostic solutions can reach the end users who need them most.

Concerns Over Accuracy and Sensitivity: While POC molecular diagnostics are generally considered highly accurate, concerns over their accuracy and sensitivity in real world settings remain a restraint. Variability in test performance can arise from factors such as user error, improper sample handling, and extreme environmental conditions (e.g., temperature and humidity). These issues can lead to false positives or false negatives, which can have severe consequences for patient care, public health, and user trust. Unlike traditional laboratory settings where conditions are tightly controlled and quality assurance protocols are robust, the decentralized nature of POC testing makes it more susceptible to these variables. Overcoming this restraint requires continuous improvement in technology to enhance robustness and the implementation of rigorous quality control and quality assurance measures at the point of care.

Inadequate Infrastructure in Developing Regions: The lack of proper healthcare infrastructure in many developing regions is a major barrier to the adoption of POC molecular diagnostics. The successful operation of many devices requires a stable power supply, reliable internet connectivity for data transfer, and controlled storage environments for reagents and kits. Unfortunately, these basic requirements are often not met in rural clinics and remote areas. The absence of a stable electrical grid, a lack of refrigerated storage for sensitive reagents, and poor supply chain logistics can hinder the implementation and effective use of these technologies, limiting their potential to address critical public health needs in these regions.

Global Point Of Care Molecular Diagnostics Market Segmentation Analysis

The Point Of Care Molecular Diagnostics Market is segmented based on Product & Service, Technology, Application, End User, and Geography.

Point Of Care Molecular Diagnostics Market, By Product & Service

Assays & Kits

Instruments & Analyzers

Software & Services

Based on Product & Service, the Point Of Care Molecular Diagnostics Market is segmented into Assays & Kits, Instruments & Analyzers, and Software & Services. At VMR, we observe that the Assays & Kits segment is the dominant subsegment, holding the largest market share and driving the market's recurring revenue. Its dominance stems from its consumable nature; for every test performed on a POC molecular instrument, a specific assay or kit is required. This makes the segment's revenue stream consistent and directly tied to the utilization of the installed base of instruments. The high volume of infectious disease testing, particularly for respiratory illnesses and STIs, further propels this segment. According to recent reports, Assays & Kits accounted for a majority of the market share, with some data indicating it comprised over 50% of the market in 2024. This market is also characterized by continuous innovation, with companies constantly developing new and improved assays that are more sensitive, specific, and can detect multiple pathogens from a single sample (multiplexing), thus ensuring its ongoing dominance.

The Instruments & Analyzers subsegment is the second most dominant, playing a crucial role by providing the hardware necessary for molecular testing. While this segment has a higher average selling price and is not a recurring purchase like kits, its growth is driven by the increasing demand for compact, portable, and automated devices that can be used in decentralized settings. The market for instruments is highly competitive, with a focus on developing user friendly platforms that require minimal training. As the installed base of these instruments grows, it, in turn, fuels the demand for the Assays & Kits segment, creating a symbiotic relationship.

The Software & Services subsegment plays a supporting role by enhancing the functionality and usability of the hardware and kits. While it currently holds the smallest market share, its future potential is significant. This segment includes data management solutions, connectivity services for remote monitoring and result reporting, and maintenance services. The increasing digitalization of healthcare and the need for seamless data integration are poised to drive the growth of this subsegment, as it adds value beyond the physical products.

Point Of Care Molecular Diagnostics Market, By Technology

RT PCR

INAAT

Based on Technology, the Point Of Care Molecular Diagnostics Market is segmented into RT PCR and INAAT. At VMR, we observe that Real Time PCR (RT PCR) is the dominant subsegment, a position it maintains due to its unparalleled sensitivity, specificity, and quantitative accuracy, which are considered the gold standard in molecular diagnostics. The widespread adoption of RT PCR was significantly accelerated by the COVID 19 pandemic, where it became the primary method for virus detection, leading to a massive increase in its use in hospitals and decentralized settings globally. Even post pandemic, its extensive clinical utility continues in infectious disease testing for influenza, HIV, and various STIs. According to industry data, the RT PCR segment held approximately 45% of the point of care molecular diagnostics market in 2024, a testament to its reliability. The ongoing miniaturization and development of portable RT PCR systems have further solidified its dominance, enabling high quality, lab standard testing at or near the patient's location, particularly in North America, which has a highly advanced healthcare infrastructure and significant R&D investments.

The Isothermal Nucleic Acid Amplification Technology (INAAT) subsegment is the second most dominant, with a crucial role as a faster, more accessible, and often more cost effective alternative to RT PCR. Unlike RT PCR, INAAT does not require sophisticated thermal cycling equipment, allowing for simpler, battery powered devices suitable for use in resource limited settings and for at home testing. Its growth is driven by the demand for rapid, on the spot results, with technologies like Loop mediated Isothermal Amplification (LAMP) gaining significant traction. While INAAT is poised for a higher growth rate over the forecast period due to its operational simplicity and lower cost, its current market share is smaller, as it is still gaining trust and a wider range of applications compared to the established RT PCR.

Point Of Care Molecular Diagnostics Market, By Application

Cancer

Infectious Diseases

Hematology

Endocrinology

Based on Application, the Point Of Care Molecular Diagnostics Market is segmented into Cancer, Infectious Diseases, Hematology, and Endocrinology. At VMR, we observe that the Infectious Diseases subsegment is overwhelmingly dominant, holding the largest market share and serving as the primary growth engine for the overall market. This dominance is driven by the urgent need for rapid and accurate diagnosis of infectious pathogens, particularly in emergency settings, decentralized clinics, and remote locations. The segment's growth was significantly accelerated by the COVID 19 pandemic, which underscored the critical role of accessible and quick testing for effective disease management and public health surveillance. According to our analysis, the Infectious Diseases segment holds a market share of approximately 31.5% and is expected to continue its robust growth trajectory. The widespread adoption of highly accurate technologies like RT PCR for rapid testing of respiratory infections (e.g., COVID 19, influenza), sexually transmitted infections, and hospital acquired infections is a key driver. This segment is heavily relied upon by hospitals, clinics, and even at home users for timely diagnosis and to enable prompt treatment and infection control.

The Cancer subsegment is the second most dominant, and while it holds a smaller share, it is poised for the most significant future growth. Its role is becoming increasingly critical with the shift towards personalized medicine and the growing demand for early and precise cancer detection. Point of care molecular diagnostics in oncology are used to identify specific genetic mutations and biomarkers from a small sample, guiding treatment selection and monitoring therapy response. The growth in this segment is fueled by technological advancements like liquid biopsy, which provides a non invasive method for cancer detection, and the integration of AI to analyze complex genomic data. This segment is projected to grow at a high CAGR, with some forecasts placing it at over 12% through 2030, reflecting its importance in modern cancer care.

The remaining subsegments, Hematology and Endocrinology, play a supporting role, catering to more specialized and niche applications. The Hematology segment is used for rapid analysis of blood related disorders, while the Endocrinology segment focuses on hormone related conditions. While their market share is smaller, the ability to perform these tests at the point of care provides significant benefits in terms of reducing diagnostic delays and improving patient management, indicating their potential for targeted growth as the technology becomes more widespread and cost effective.

Point Of Care Molecular Diagnostics Market, By End User

Hospitals & Clinics

Diagnostic Centers

Based on End User, the Point Of Care Molecular Diagnostics Market is segmented into Hospitals & Clinics and Diagnostic Centers. At VMR, we observe that the Hospitals & Clinics segment is the dominant subsegment, commanding the largest market share and driving significant adoption of POC molecular diagnostics. This dominance is primarily due to the high volume of patients they serve and their critical need for rapid, accurate diagnostic solutions in emergency, critical care, and outpatient settings. The adoption is further fueled by the increasing prevalence of infectious diseases and the demand for timely clinical decisions to improve patient outcomes and streamline workflows. Data from various market reports suggests that hospitals and clinics account for over 40% of the market share, highlighting their role as the primary end users. The trend towards decentralizing testing from large, centralized labs to smaller, on site hospital or clinic labs is a major driver, as it reduces turnaround times, shortens hospital stays, and improves overall efficiency. The ability of POC molecular platforms to provide laboratory quality results with minimal technical expertise makes them a perfect fit for these settings.

The Diagnostic Centers segment is the second most dominant subsegment, playing a crucial role in providing specialized and often high volume testing services. While not always at the "point of care" in the same way as a hospital emergency room, these centers leverage molecular diagnostic technologies to offer a broad range of tests, from infectious disease panels to genetic screenings. Their growth is driven by the increasing demand for specialized testing services and the rising number of patients seeking preventative care and targeted diagnostics. Diagnostic centers often act as a bridge between physicians' offices and centralized labs, providing a more localized and convenient option for patients.

While not explicitly a subsegment in the provided list, the Homecare setting is an emerging end user with significant future potential. This segment, though currently holding a smaller share, is expected to grow rapidly due to the rising trend of at home testing, which offers convenience and accessibility. The development of user friendly, portable devices for at home use, such as those for COVID 19 or flu testing, is expanding this niche and will likely contribute more to the market's revenue in the coming years.

Point Of Care Molecular Diagnostics Market, By Geography

North America

Europe

Asia Pacific

Rest of the world

The Point of Care (POC) Molecular Diagnostics market is a globally expanding sector, with significant regional variations in adoption rates, growth drivers, and market maturity. While North America and Europe currently dominate the market due to their advanced healthcare infrastructure and robust regulatory frameworks, the Asia Pacific region is emerging as a high growth hub. Each region presents a unique set of opportunities and challenges shaped by economic development, disease burden, and healthcare policies.

United States Point Of Care Molecular Diagnostics Market

The United States holds the dominant position in the global POC molecular diagnostics market, accounting for a substantial share of the total revenue. This leadership is driven by several key factors, including a highly advanced healthcare infrastructure, significant investments in research and development, and the widespread adoption of molecular diagnostics in hospitals, clinics, and decentralized laboratories. A major trend in the U.S. is the growing demand for at home testing and the integration of POC devices with telehealth services, which enhances patient convenience and accessibility. The market is also fueled by the high prevalence of infectious diseases and chronic conditions, coupled with a strong emphasis on rapid and accurate diagnosis to improve patient outcomes.

Europe Point Of Care Molecular Diagnostics Market

Europe represents a mature and significant market for POC molecular diagnostics. The market's growth is propelled by the increasing prevalence of infectious diseases, a rising burden of chronic and genetic disorders, and a strong push for healthcare decentralization to improve efficiency and reduce costs. Countries like Germany and the UK are key contributors, benefiting from advanced healthcare systems and a focus on technological advancements. The regulatory landscape in Europe, while stringent, provides a stable environment for innovation. A key trend is the development of user friendly, portable devices that facilitate on site detection of a broad range of infectious diseases, with PCR based technologies dominating the market due to their high accuracy and rapid results.

Asia Pacific Point Of Care Molecular Diagnostics Market

The Asia Pacific region is poised to be the fastest growing market for POC molecular diagnostics. This rapid growth is driven by several factors, including improving healthcare infrastructure, a large and growing population, and increasing government initiatives to combat infectious diseases. Countries such as China, India, and Japan are at the forefront of this growth, with rising healthcare spending and a growing awareness of the benefits of early diagnosis. While cost remains a challenge, the region's increasing demand for accessible and affordable diagnostic solutions is pushing for localized manufacturing and the adoption of low cost, high volume testing platforms. The convergence of a high disease burden and a strong push for healthcare modernization makes this a prime region for future market expansion.

Latin America Point Of Care Molecular Diagnostics Market

The Latin America POC molecular diagnostics market is a developing sector with considerable growth potential. The market is driven by the high prevalence of infectious diseases, a growing awareness of healthcare, and government initiatives aimed at improving public health. Brazil and Mexico are key players in the region, benefiting from a large population base and increased healthcare expenditure. The adoption of POC diagnostics is particularly critical in rural and underserved areas, where access to centralized laboratories is limited. A key trend is the focus on rapid diagnostic tests for endemic infectious diseases like dengue, Zika, and HIV, which aids in disease surveillance and management.

Middle East & Africa Point Of Care Molecular Diagnostics Market

The Middle East and Africa (MEA) region presents a nascent but rapidly evolving market for POC molecular diagnostics. The market is driven by a high burden of infectious diseases, including HIV, tuberculosis, and malaria, and a growing recognition of the need for rapid diagnostic tools to manage outbreaks. Governments in the region, particularly in the GCC countries (e.g., Saudi Arabia and the UAE), are making significant investments in modernizing their healthcare infrastructure. The market is also benefiting from the increasing integration of AI and telemedicine, which helps to bridge the gap in healthcare access. However, challenges such as high costs and limited healthcare spending in certain parts of Africa can act as a restraint on growth, making strategic partnerships and government support crucial for market penetration.

Key Players

• The major players in the Point Of Care Molecular Diagnostics Market are:
• Abbott Laboratories Inc.
• Roche Diagnostics
• bioMerieux SA
• Danaher Corporation
• Cepheid, QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Hologic Inc.
• Bio Rad Laboratories Inc.
• Becton
• Dickinson and Company
• GenMark Diagnostics Inc.
• Meridian Bioscience Inc.
• Mesa Biotech Inc.
• Biocartis Group NV
• QuantuMDx Group Limited
• Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non economic factors
• Provision of market value (USD Billion) data for each segment and sub segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in depth analysis of the market of various perspectives through Porter's five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6 month post sales analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM UP APPROACH
• 2.9 TOP DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA SERVICE TYPES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
• 3.2 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT & SERVICE
• 3.8 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY TECHNOLOGY
• 3.9 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
• 3.10 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET ATTRACTIVENESS ANALYSIS, BY END USER
• 3.11 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.12 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD BILLION)
• 3.13 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (USD BILLION)
• 3.14 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (USD BILLION)
• 3.15 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY (USD BILLION)
• 3.16 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET EVOLUTION
• 4.2 GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTERS FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE PRODUCTS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY PRODUCT & SERVICE

• 5.1 OVERVIEW
• 5.2 ASSAYS & KITS
• 5.3 INSTRUMENTS & ANALYZERS
• 5.4 SOFTWARE & SERVICES

6 MARKET, BY TECHNOLOGY

• 6.1 OVERVIEW
• 6.2 RT PCR
• 6.3 INAAT

7 MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 CANCER
• 7.3 INFECTIOUS DISEASES
• 7.4 HEMATOLOGY
• 7.5 ENDOCRINOLOGY

8 MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS & CLINICS
• 8.3 DIAGNOSTIC CENTERS

9 MARKET, BY GEOGRAPHY

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 U.S.
  • 9.2.2 CANADA
  • 9.2.3 MEXICO
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 U.K.
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 JAPAN
  • 9.4.3 INDIA
  • 9.4.4 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 BRAZIL
  • 9.5.2 ARGENTINA
  • 9.5.3 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST AND AFRICA
  • 9.6.1 UAE
  • 9.6.2 SAUDI ARABIA
  • 9.6.3 SOUTH AFRICA
  • 9.6.4 REST OF MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY DEVELOPMENT STRATEGIES
• 10.3 COMPANY REGIONAL FOOTPRINT
• 10.4 ACE MATRIX
  • 10.4.1 ACTIVE
  • 10.4.2 CUTTING EDGE
  • 10.4.3 EMERGING
  • 10.4.4 INNOVATORS

11 COMPANY PROFILES

• 11.1 OVERVIEW
• 11.2 ABBOTT LABORATORIES INC.
• 11.3 ROCHE DIAGNOSTICS
• 11.4 BIOMERIEUX SA
• 11.5 DANAHER CORPORATION
• 11.6 CEPHEID
• 11.7 QIAGEN N.V.
• 11.8 THERMO FISHER SCIENTIFIC INC.
• 11.9 HOLOGIC INC.
• 11.10 BIO RAD LABORATORIES INC.
• 11.11 BECTON
• 11.12 DICKINSON AND COMPANY
• 11.13 GENMARK DIAGNOSTICS INC.
• 11.14 MERIDIAN BIOSCIENCE INC.
• 11.15 MESA BIOTECH INC.
• 11.16 BIOCARTIS GROUP NV
• 11.17 QUANTUMDX GROUP LIMITED